سعر اتكوليبوكس 10 مجم 30 قرص 2023

Atorvastatin 10 mg chewable tablets (HMG-CoA reductase inhibitor, lipid-lowering), pack of 30 tablets (3 strips), Atco Pharma.

• Adjunct to diet for reduction of elevated total-C, LDL-C, apolipoprotein B and triglycerides in primary hypercholesterolaemia (including heterozygous familial) or combined (mixed) hyperlipidaemia when response to diet is inadequate.Population: Adults, adolescents and children aged 10 years or olderelectronic medicines compendium (eMC), UK
• Reduction of total-C and LDL-C in homozygous familial hypercholesterolaemia, as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.Population: Adultselectronic medicines compendium (eMC), UK
• Prevention of cardiovascular events in adults estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.Population: Adultselectronic medicines compendium (eMC), UK

• Common: nasopharyngitis, allergic reactions, hyperglycaemia, headache, pharyngolaryngeal pain, epistaxis, constipation, flatulence, dyspepsia, nausea, diarrhoea, myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain, abnormal liver function tests and increased blood CK. Rare: myopathy, myositis, rhabdomyolysis, cholestasis.International label, same formulation · electronic medicines compendium (eMC), UK

• Hypersensitivity to atorvastatin or any excipient; active liver disease or unexplained persistent serum transaminases >3 x ULN; pregnancy, breastfeeding and women of child-bearing potential not using appropriate contraception; treatment with glecaprevir/pibrentasvir.International label, same formulation · electronic medicines compendium (eMC), UK

• Perform liver function tests before and periodically during treatment; reduce dose or withdraw if transaminases persist >3 x ULN; caution with substantial alcohol intake or history of liver disease.International label, same formulation · electronic medicines compendium (eMC), UK
• Skeletal muscle effects: myalgia, myositis and myopathy that may progress to rhabdomyolysis; very rare immune-mediated necrotising myopathy. Measure CK before treatment in patients with predisposing factors; do not start if CK >5 x ULN; stop if CK markedly elevated or rhabdomyolysis suspected. Risk increased with potent CYP3A4/transport-protein inhibitors, fibrates, some HCV antivirals and daptomycin; do not co-administer with systemic fusidic acid (or within 7 days of stopping it).International label, same formulation · electronic medicines compendium (eMC), UK
• Higher incidence of haemorrhagic stroke with atorvastatin 80 mg in patients with recent stroke/TIA without CHD (SPARCL post-hoc); weigh risk in patients with prior haemorrhagic stroke or lacunar infarct.International label, same formulation · electronic medicines compendium (eMC), UK

• Potent CYP3A4 or transport-protein inhibitors (e.g. ciclosporin, clarithromycin, telithromycin, itraconazole, ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, letermovir)Increase atorvastatin exposure and the risk of myopathy/rhabdomyolysis; avoid where possible or use a lower starting and maximum dose with monitoring.electronic medicines compendium (eMC), UK
• Glecaprevir/pibrentasvirContraindicated with atorvastatin.electronic medicines compendium (eMC), UK
• Elbasvir/grazoprevir; letermovirAtorvastatin dose should not exceed 20 mg/day; atorvastatin not recommended with letermovir plus ciclosporin.electronic medicines compendium (eMC), UK

• Contraindicated in pregnancy; safety not established; rare congenital anomalies reported after intrauterine exposure to statins; should not be used by women who are pregnant, trying to become pregnant or suspect pregnancy.International label, same formulation · electronic medicines compendium (eMC), UK
• Contraindicated during breastfeeding; excretion into human milk unknown (similar milk and plasma levels in rats).International label, same formulation · electronic medicines compendium (eMC), UK

• Atorvastatin: Inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis.